Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

361275

Sigma-Aldrich

3′-Desoxy-3′-fluorthymidin

97%

Synonym(e):

3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C10H13FN2O4
CAS-Nummer:
25526-93-6
Molekulargewicht:
244.22
MDL-Nummer:
MFCD00056058
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24862180
NACRES:
NA.22

Qualitätsniveau

100

Assay

97%

Form

solid

mp (Schmelzpunkt)

176-178 °C (lit.)

Lagertemp.

2-8°C

SMILES String

CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

InChIKey

UXCAQJAQSWSNPQ-XLPZGREQSA-N

Angaben zum Gen

human ... TK2(7084)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Anwendung

Promising antiviral agent possessing activity similar to other 3′-deoxy-3′-substituted thymidines.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Eliot T McKinley et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)
Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of
Nicolas Graf et al.
European journal of nuclear medicine and molecular imaging, 40(1), 34-43 (2012-10-12)
Positron emission tomography (PET) with the thymidine analogue [(18)F]fluorothymidine ([(18)F]FLT) has been shown to detect early response to chemotherapy in high-grade lymphoma. In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG)
Tyler J Bradshaw et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(11), 1931-1937 (2013-09-18)
Intratumor heterogeneity in biologic properties and in relationships between various phenotypes may present a challenge for biologically targeted therapies. Understanding the relationships between different phenotypes in individual tumor types could help inform treatment selection. The goal of this study was
A Van Aerschot et al.
Journal of medicinal chemistry, 32(8), 1743-1749 (1989-08-01)
A series of 2'- and 3'-fluorinated 2',3'-dideoxynucleosides and 3'-azido-2',3'-dideoxynucleosides were synthesized and evaluated for their inhibitory activity against human immunodeficiency virus-1 (HIV-1) replication in MT-4 cells. Neither conversion of 3'-fluoro- or 3'-azido-2',3'-dideoxyadenosine to the corresponding inosine derivatives nor 8-bromination of
Deniz Kahraman et al.
Clinical nuclear medicine, 37(11), 1058-1064 (2012-10-03)
The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.